中央实验室市场、机会、成长动力、产业趋势分析与预测，2024-2032

Central Lab Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球中心实验室市场价值约为 31 亿美元。这一成长主要得益于对外包测试服务的日益重视以及研发投资的大幅增加。

出于对成本效率、高品质结果和专业测试能力的追求，组织越来越多地转向外包测试服务。美国食品药物管理局(FDA) 报告称，2022 年利用外包中心实验室服务的临床试验激增25%，较2019 年显着增加。确保准确、快速的测试，推动市场成长。

技术进步正在重塑实验室服务的格局。下一代定序 (NGS)、自动化实验室系统、人工智慧、机器学习、即时检测突破和复杂的生物感测器等创新正在提高精度和效率，同时扩大所提供的服务范围。这些发展对于定义产业发展轨迹至关重要。

中央实验室市场根据服务、应用、最终用途和区域进行细分。

生物标记服务领域在市场上占据主导地位，2023 年收入为 9.345 亿美元。这些生物标记对于识别特定疾病途径和预测患者对治疗的反应至关重要，这使得它们对于开发个人化治疗至关重要。这一趋势极大地推动了对生物标记服务的需求。製药和生物技术产业依靠生物标记来提高药物开发的效率和效果，进一步拉动对生物标记服务的需求。

中央实验室市场根据肿瘤学、神经学、心臟病学、传染病和其他应用的应用进行分类。肿瘤学领域预计将主导中央实验室产业，预计到 2032 年收入将达到 16 亿美元。中心实验室对于提供癌症专业检测和诊断服务至关重要，包括基因分析、生物标记分析和组织病理学，以支援肿瘤学研究和临床实践。液体活检、新一代定序 (NGS) 和先进成像等诊断技术的进步使得精确、早期检测和个人化治疗成为可能，从而推动了对肿瘤学专业实验室服务的需求。

到 2023 年，北美中心实验室市场的收入将达到 11 亿美元，预计在分析时间内将大幅成长。北美对个人化医疗的日益关注增加了对先进诊断服务和生物标记的需求，从而推动了整个北美中心实验室的需求。癌症和糖尿病等慢性病发病率的上升需要更全面的测试和研究，从而推动了北美中心实验室产业的成长。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

A.P. Moller Holding A/S
ACM Global Laboratories
BioAgilytix Labs
Cerba Research
Cirion Biopharma Research Inc.
Covance Inc.
Eurofins Scientific
Frontage Laboratories
ICON Central Laboratories
LabConnect
Laboratory Corporation of America Holding
Lambda Therapeutics Research Ltd
Medpace, Inc.
Parexel International Corporation
Quest Diagnostics
Versiti

简介目录

Product Code: 10831

The Global Central Lab Market was valued at approximately USD 3.1 billion in 2023. Projections indicate it will grow to around USD 5.1 billion by 2032, achieving a CAGR of 5.8% during the forecast period. This growth is primarily fueled by a rising emphasis on outsourcing testing services and a significant uptick in research and development investments.

Organizations are increasingly turning to outsourced testing services, motivated by the pursuit of cost efficiency, high-quality results, and specialized testing capabilities. The U.S. Food and Drug Administration (FDA) reported a 25% surge in clinical trials leveraging outsourced central laboratory services in 2022, a marked increase from 2019. By outsourcing, organizations can focus on their primary activities, while central labs ensure accurate and swift testing, propelling the market's growth.

Technological advancements are reshaping the landscape of lab services. Innovations such as next-generation sequencing (NGS), automated laboratory systems, artificial intelligence, machine learning, point-of-care testing breakthroughs, and sophisticated biosensors are enhancing precision and efficiency while broadening the range of services offered. These developments are pivotal in defining the industry's trajectory.

The central lab market is segmented based on services, application, end-use, and region.

The biomarker services segment dominated the market with a revenue of USD 934.5 million in 2023. Precision medicine, which customizes treatments based on individual genetic, environmental, and lifestyle factors, heavily relies on biomarkers. These biomarkers are essential for identifying specific disease pathways and predicting patient responses to therapies, making them critical for developing personalized treatments. This trend significantly drives the demand for biomarker services. The pharmaceutical and biotech industries rely on biomarkers to enhance the efficiency and effectiveness of drug development, further boosting the demand for biomarker services.

The central lab market is categorized based on applications into oncology, neurology, cardiology, infectious diseases, and other applications. The oncology segment is anticipated to dominate the central lab industry, with a projected revenue of USD 1.6 billion by 2032. The high prevalence of cancer drives the demand for extensive cancer research, diagnostics, and treatment monitoring. Central labs are crucial in providing specialized testing and diagnostic services for cancer, including genetic profiling, biomarker analysis, and histopathology, to support oncology research and clinical practice. Advancements in diagnostics, such as liquid biopsy, next-generation sequencing (NGS), and advanced imaging, enable precise, early detection and personalized treatment, driving the need for specialized lab services in oncology.

In 2023, North America central lab market accounted for USD 1.1 billion in revenue and is predicted to witness substantial growth over the analysis timeline. The increasing focus on personalized medicine in North America boosts demand for advanced diagnostic services and biomarkers, driving the demand for central labs across North America. The rising incidence of chronic diseases such as cancer and diabetes necessitate more comprehensive testing and research, fueling the growth of central lab industry in North America.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing emphasis on outsourcing of testing services
  - 3.2.1.2 Technological advancements in testing equipment
  - 3.2.1.3 Extensive growth in research and development investments
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent government regulations and compliance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Genetic services
5.3 Biomarker services
5.4 Microbiology services
5.5 Anatomic pathology/histology
5.6 Specimen management and storage
5.7 Other services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 Neurology
6.4 Cardiology
6.5 Infectious diseases
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical and biotechnology companies
7.3 Academic and research institutes
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa